STERIS plc $STE Shares Bought by Foster Victor Wealth Advisors LLC

Foster Victor Wealth Advisors LLC grew its stake in STERIS plc (NYSE:STE) by 6.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 80,029 shares of the medical equipment provider’s stock after acquiring an additional 4,646 shares during the quarter. STERIS comprises approximately 1.2% of Foster Victor Wealth Advisors LLC’s investment portfolio, making the stock its 21st biggest position. Foster Victor Wealth Advisors LLC owned about 0.08% of STERIS worth $19,407,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Trust Point Inc. grew its holdings in shares of STERIS by 21.2% in the third quarter. Trust Point Inc. now owns 1,090 shares of the medical equipment provider’s stock valued at $270,000 after purchasing an additional 191 shares during the period. Congress Asset Management Co. boosted its holdings in STERIS by 8.4% in the 3rd quarter. Congress Asset Management Co. now owns 133,224 shares of the medical equipment provider’s stock valued at $32,965,000 after purchasing an additional 10,281 shares during the last quarter. Perpetual Ltd grew its stake in shares of STERIS by 1.0% in the 3rd quarter. Perpetual Ltd now owns 55,659 shares of the medical equipment provider’s stock valued at $13,772,000 after buying an additional 542 shares during the period. Addenda Capital Inc. purchased a new stake in shares of STERIS in the 3rd quarter valued at approximately $4,660,000. Finally, Dynamic Advisor Solutions LLC increased its holdings in shares of STERIS by 5.8% during the 3rd quarter. Dynamic Advisor Solutions LLC now owns 1,295 shares of the medical equipment provider’s stock worth $320,000 after buying an additional 71 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Analysts Set New Price Targets

STE has been the topic of a number of recent analyst reports. Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $273.50.

STERIS Stock Performance

NYSE:STE opened at $254.81 on Friday. STERIS plc has a fifty-two week low of $200.98 and a fifty-two week high of $268.60. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37. The company has a 50 day moving average price of $252.57 and a 200 day moving average price of $244.15. The stock has a market capitalization of $25.01 billion, a P/E ratio of 36.61 and a beta of 1.01.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. STERIS had a return on equity of 14.43% and a net margin of 12.07%.The company had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same period in the prior year, the firm earned $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Equities research analysts forecast that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Tuesday, November 18th were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Tuesday, November 18th. STERIS’s dividend payout ratio (DPR) is 36.21%.

Insider Transactions at STERIS

In other STERIS news, VP Renato Tamaro sold 5,036 shares of STERIS stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total value of $1,297,021.80. Following the completion of the transaction, the vice president directly owned 5,695 shares of the company’s stock, valued at $1,466,747.25. The trade was a 46.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Daniel A. Carestio sold 159 shares of the stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $241.82, for a total transaction of $38,449.38. Following the sale, the chief executive officer directly owned 51,096 shares in the company, valued at $12,356,034.72. This represents a 0.31% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 25,203 shares of company stock valued at $6,624,667. 1.07% of the stock is owned by insiders.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.